Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.48 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.48 |
| ▸ | DHODH | Q02127 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TYK2 | P29597 | 1/20 | 0.45 |
| ▸ | F2R | P25116 | 2/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2316708 | 0.87 | RAB9A (0.51) | SMN1; SMN2ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL2307990 | 0.87 | MEN1 (0.52) | SMN1; SMN2ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL2313062 | 0.87 | NPC1 (0.50) | SMN1; SMN2ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL2311455 | 0.87 | MEN1 (0.48) | SMN1; SMN2ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL2311049 | 0.87 | PKM (0.49) | NPC1RAB9AKMT2AHPGDTP53 | |
| SCHEMBL12879233 | 0.85 | GPR27 (0.45) | SMN1; SMN2ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL2310529 | 0.85 | KCNK3 (0.56) | SMN1; SMN2ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL2309884 | 0.85 | MEN1 (0.42) | SMN1; SMN2ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL2308403 | 0.85 | NPC1 (0.52) | SMN1; SMN2ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL2313973 | 0.84 | PTGS1 (0.56) | KCNK3KCNK9F2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190256530-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. | 2019-08-22 | — | — | US | disclosed |
| US-20190256530-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. | 2019-08-22 | — | — | US | disclosed |
| US-10301329-B2 | Boron-containing small molecules as antiprotozoal agents | ANACOR PHARMACEUTICALS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-10301329-B2 | Boron-containing small molecules as antiprotozoal agents | ANACOR PHARMACEUTICALS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20160340369-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, LLC | 2016-11-24 | — | — | US | disclosed |
| US-20160340369-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, LLC | 2016-11-24 | — | — | US | disclosed |
| US-9440994-B2 | Boron containing small molecules as antiprotozoal agents | ANACOR PHARMACEUTICALS, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9440994-B2 | Boron containing small molecules as antiprotozoal agents | ANACOR PHARMACEUTICALS, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-20110190235-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190235-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2011019618-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190235-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | BTD, BAD, BRI3BP | SMN1; SMN2 3037/4885ALDH1A1 4684/4885NPC1 216/4885 |
| US-20160340369-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | BTD, BAD, BRI3BP | SMN1; SMN2 3037/4885ALDH1A1 4684/4885NPC1 216/4885 |
| US-10301329-B2 | Boron-containing small molecules as antiprotozoal agents | BTD, BAD, BRI3BP | SMN1; SMN2 3037/4885ALDH1A1 4684/4885NPC1 216/4885 |
| US-20190256530-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | BTD, BAD, BRI3BP | SMN1; SMN2 3037/4885ALDH1A1 4684/4885NPC1 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.